Comparison among Neuroblastoma Stages Suggests the Involvement of Mitochondria in Tumor Progression

Neuroblastoma (NB) is the most common extracranial tumor of early childhood and accounts for 15% of all pediatric cancer mortalities. However, the precise pathways and genes underlying its progression are unknown. Therefore, we performed a differential gene expression analysis of neuroblastoma stage...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2023-02, Vol.11 (2), p.596
Main Authors: Cagnin, Stefano, Knedlik, Tomas, Vianello, Caterina, Magalhães Rebelo, Ana Paula, De Mario, Agnese, Giacomello, Marta
Format: Article
Language:English
Subjects:
Abdomen
Apoptosis
Bone marrow
Brief Report
Cancer
Cell cycle
Children
cytoskeleton
Datasets
Development and progression
differentially expressed genes
Endoplasmic reticulum
Gene expression
Health aspects
Homeostasis
Kinases
Lymphoma
Medical prognosis
Metastasis
microtubules
Mitochondria
Mutation
Nervous system
Neuroblastoma
Pathogenesis
Pediatrics
Proteins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroblastoma (NB) is the most common extracranial tumor of early childhood and accounts for 15% of all pediatric cancer mortalities. However, the precise pathways and genes underlying its progression are unknown. Therefore, we performed a differential gene expression analysis of neuroblastoma stage 1 and stage 4 + 4S to discover biological processes associated with NB progression. From this preliminary analysis, we found that NB samples (stage 4 + 4S) are characterized by altered expression of some proteins involved in mitochondria function and mitochondria-ER contact sites (MERCS). Although further analyses remain necessary, this review may provide new hints to better understand NB molecular etiopathogenesis, by suggesting that MERCS alterations could be involved in the progression of NB.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11020596